Showing 8631-8640 of 9758 results for "".
- Study: Vagus Nerve Stimulation Improves ETR Symptomshttps://practicaldermatology.com/news/study-vagus-nerve-stimulation-improves-etr-symptoms/2483900/Results from a recent study suggest transcutaneous auricular vagus nerve stimulation (taVNS) could be a viable therapeutic option for patients with erythematotelangiectatic rosacea (ETR). Researchers for the randomized, double-
- IFPA Highlights Patient Voices in Global Health Policy at UN Panelhttps://practicaldermatology.com/news/ifpa-highlights-patient-voices-in-global-health-policy/2483540/The International Federation of Psoriatic Disease Associations (IFPA) issued a call to global policymakers to recognize psoriatic disease as a serious noncommunicable disease (NCD) with system-wide implications at the 80th UN General Assembly in New York.
- From EADV: Povorcitinib Maintains Efficacy Through 24 Weeks in STOP-HS Programhttps://practicaldermatology.com/news/from-eadv-povorcitinib-maintains-efficacy-through-24-weeks-in-hs-phase-3-data/2483429/New 24-week results from the phase 3 STOP-HS trial program suggest that investigational oral JAK1 inhibitor povorcitinib provided sustained clinical benefits in adults with moderate to severe hidradenitis suppurativa (HS), according to findings presented at the 2025
- Incyte to Present STOP-HS, TRuE-PN Trials at EADV 2025https://practicaldermatology.com/news/late-breaking-hs-and-pn-data-to-anchor-incytes-eadv-presentations/2483330/Incyte announced that it will present new data from studies throughouts its dermatology pipeline at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, according to a press release from the manufacturer.
- NB-UVB Phototherapy Effective for Psoriasis in Skin of Colorhttps://practicaldermatology.com/news/nb-uvb-phototherapy-effective-for-psoriasis-in-skin-of-color/2483263/A new systematic review and meta-analysis confirms that narrowband ultraviolet B (NB-UVB) phototherapy is effective for psoriasis in patients with skin of color, underscoring its role as a valuable treatment option despite the widespread adoption of biologics and systemic agents.
- Early Childhood Stress Tied to Psoriasis Riskhttps://practicaldermatology.com/news/early-childhood-stress-tied-to-psoriasis-risk/2483262/A prospective cohort study from Sweden suggests that early childhood stress, particularly disruptions in family structure, may increase the risk of developing psoriasis later in life. The research, published in the Journal of Investigative Dermatology
- Recall of DermaRite Industries Products Expandshttps://practicaldermatology.com/news/recall-of-dermarite-sanitizers-and-cleansers-expands/2483166/Citing an abundance of caution, DermaRite Industries has announced it is expanding its voluntary recall of hand sanitizers and cleansers initiated on
- Bimekizumab Outperforms IL-17 Inhibitors in Real-World Psoriasis Studyhttps://practicaldermatology.com/news/bimekizumab-shows-edge-over-il-17-inhibitors-in-polish-real-world-psoriasis-study/2482980/Bimekizumab demonstrated a faster and more robust response than secukinumab and ixekizumab in a real-world cohort of Polish patients with moderate-to-severe plaque psoriasis. Researchers conducted a retrospective analysis fro
- DermaRite Recalls Four Skin Care Products Over Burkholderia cepacia Contamination Riskhttps://practicaldermatology.com/news/dermarite-recalls-four-skin-care-products-over-burkholderia-cepacia-contamination-risk/2476092/DermaRite Industries has issued a nationwide recall of four over-the-counter antiseptic and analgesic products after tests detected contamination with Burkholderia cepacia complex (BCC), according to a statement released by
- Report: IL-17 Therapies Target PsO and More, Poised for Growthhttps://practicaldermatology.com/news/report-il-17-therapies-target-pso-and-more-poised-for-growth/2475920/The interleukin-17 (IL-17) inhibitors market is expected to see sustained growth through 2034, driven primarily by next-gen agents and expanding indications in dermatology and rheumatology, according to a new report. Novel ag